- Home
- BAFN vs ICCM Comparison
BAFN vs ICCM Comparison
Compare BAFN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAFN
- ICCM
- Stock Information
- Founded
- BAFN 1999
- ICCM 2006
- Country
- BAFN United States
- ICCM Israel
- Employees
- BAFN N/A
- ICCM N/A
- Industry
- BAFN Savings Institutions
- ICCM
- Sector
- BAFN Finance
- ICCM
- Exchange
- BAFN Nasdaq
- ICCM Nasdaq
- Market Cap
- BAFN 63.2M
- ICCM 61.1M
- IPO Year
- BAFN N/A
- ICCM N/A
- Fundamental
- Price
- BAFN $8.78
- ICCM $1.05
- Analyst Decision
- BAFN
- ICCM Strong Buy
- Analyst Count
- BAFN 0
- ICCM 1
- Target Price
- BAFN N/A
- ICCM $2.00
- AVG Volume (30 Days)
- BAFN 24.3K
- ICCM 1.9M
- Earning Date
- BAFN 10-23-2025
- ICCM 08-13-2025
- Dividend Yield
- BAFN 3.74%
- ICCM N/A
- EPS Growth
- BAFN 100.65
- ICCM N/A
- EPS
- BAFN 1.89
- ICCM N/A
- Revenue
- BAFN $78,211,000.00
- ICCM $2,787,000.00
- Revenue This Year
- BAFN N/A
- ICCM $62.11
- Revenue Next Year
- BAFN N/A
- ICCM $142.91
- P/E Ratio
- BAFN $4.60
- ICCM N/A
- Revenue Growth
- BAFN 0.67
- ICCM N/A
- 52 Week Low
- BAFN $6.40
- ICCM $0.48
- 52 Week High
- BAFN $19.75
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- BAFN 38.58
- ICCM 56.58
- Support Level
- BAFN $8.36
- ICCM $1.01
- Resistance Level
- BAFN $10.16
- ICCM $1.31
- Average True Range (ATR)
- BAFN 0.85
- ICCM 0.08
- MACD
- BAFN 0.17
- ICCM 0.03
- Stochastic Oscillator
- BAFN 58.19
- ICCM 50.94
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.